Premium
Siponimod for treating secondary progressive multiple sclerosis
Author(s) -
Chaplin Steve
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1882
Subject(s) - medicine , multiple sclerosis , physical medicine and rehabilitation , immunology
Siponimod (Mayzent) is a sphingosine‐1‐phosphate receptor modulator for the treatment of secondary progressive multiple sclerosis. This article discusses its properties, place in therapy, efficacy and adverse effects.